“After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the Committee’s investigation,” committee Chairwoman Carolyn Maloney (Democrat – New York) wrote in a memo announcing the subpoena.
“Although most of the drug companies we are examining have cooperated with the committee’s investigation, AbbVie’s noncompliance stands out as particularly egregious, which is why I am issuing this subpoena,” Maloney wrote.
AbbVie sells Humira, the best-selling drug in the world with net revenue of more than US$19.2 billion in 2019, to treat rheumatoid arthritis and other inflammatory diseases.
The committee is also seeking information on Imbruvica, which treats mantle cell lymphoma and generated net revenue of more than US$4.6 billion last year.
In a statement, AbbVie said it was “surprised and disappointed” by the subpoena, because the company had been cooperating with the committee’s investigation.
